Multifunctional Nanosystems for Precision Oncology: Real-time Monitoring and Controlled Release for Tumor-specific Treatment View PDF

^*Sahar Salam
Medicine, Yenepoya Medical College, Mangalore, Karnataka, India
Prenika Devadas Gandhi
Medicine, Metropolitan University College Of Medicine, Newgate Street, St. John’s, Antigua And Barbuda
Arshitha Channakeshava Reddy
Medicine, Akaki Tseretelli State University, Kutaisi, Georgia
Ramya Madhusudan
Medicine, Indira Gandhi Medical College & Research Institute, Kathirkamam, Puducherry, India

^*Corresponding Author:

Sahar Salam
Medicine, Yenepoya Medical College, Mangalore, Karnataka, India

Published on: 2026-02-10

Abstract

The rapid advancements in multifunctional nanosystems for precision oncology necessitate a comprehensive review to consolidate recent developments, evaluate their clinical potential, and address existing challenges. As cancer therapy shifts toward personalized approaches, integrating real-time monitoring and controlled drug release into a single platform has become critical for improving treatment efficacy and patient outcomes. This review highlights the urgent need to bridge the gap between innovative nanoplatforms and their clinical translation, emphasizing biocompatibility, scalability, and regulatory hurdles. This review provides key insights into the design and functionality of hybrid nanoparticles, nanogels, hydrogels, and magnetoliposomes, showcasing their ability to combine diagnostics and therapeutics for tumor-specific targeting. It explores stimulus-responsive mechanisms, such as pH, reactive oxygen species, and enzyme-triggered drug release, that enhance precision in oncology. Advanced real-time monitoring techniques, including fluorescence and magnetic resonance imaging (MRI)-based imaging, are examined for their role in optimizing treatment regimens. The review also discusses clinical studies demonstrating the efficacy of multifunctional nanosystems in overcoming multidrug resistance and improving therapeutic outcomes. Challenges such as biocompatibility, large-scale production, and regulatory barriers are critically analyzed to identify roadblocks in clinical adoption. Furthermore, the integration of nanosystems with immunotherapy and multimodal therapies is highlighted as a promising strategy for synergistic cancer treatment. Future research should focus on refining targeting strategies, improving biocompatibility, and developing standardized protocols for clinical application. The potential of organ-on-a-chip models to simulate tumor microenvironments and predict therapeutic responses warrants further exploration. Ultimately, this review underscores the transformative potential of multifunctional nanosystems in advancing precision oncology and calls for interdisciplinary efforts to accelerate their translation into clinical practice.

Keywords

Biocompatibility, Controlled drug release, Multifunctional nanosystems, Precision oncology, Real-time monitoring, Stimuli-responsive nanoplatforms, Targeted therapy, Theranostics

Introduction

The development of multifunctional nanosystems for precision oncology has garnered significant attention due to their potential to enable real-time tumor monitoring and controlled, tumorspecific therapeutic delivery [1-4]. Recent studies highlight various nanoplatforms designed to integrate diagnostic and therapeutic functionalities, thereby advancing personalized cancer treatment. Hybrid nanoparticles have been extensively explored for their theranostic capabilities. Raka et al. [5] emphasized that hybrid nanoparticles can incorporate fluorescence dyes, MRI contrast agents, and positron emission tomography tracers, facilitating realtime monitoring of therapy response. The biocompatibility, stability, immunogenicity, and biosafety of these systems are critical factors for clinical translation, underscoring their multifunctional potential in cancer theranostics.

Similarly, the use of polyglycolic acid coated nanoparticles demonstrates promising advancements in integrating diagnostic and therapeutic functions within a single platform. Rizwan et al. [6] discussed how these nanoparticles enable real-time monitoring and treatment optimization, highlighting their role in safer and more personalized therapeutic approaches. The ability to monitor tumor progression dynamically allows for more precise adjustments in treatment regimens. Fluorescence-based nanosystems have also been developed for highsensitivity tumor monitoring. Zhao et al. [7] introduce a fluorescence ‘Trojan horse’ nanosystem capable of detecting caspase-1 activity, a marker of apoptosis, while simultaneously delivering photothermal therapy. This approach exemplifies how multifunctional fluorescence nanosystems can provide both diagnostic insights and therapeutic action, addressing challenges in precision oncology.

Magnetoliposomes and superparamagnetic nanogels further exemplify the integration of real-time monitoring with targeted delivery [8-10]. Veloso et al. [8] describe magnetoliposomes that enable precision targeting through external magnetic fields and controlled release via magnetic hyperthermia, offering spatiotemporal control over therapy. Similarly, Pareek et al. [11] review superparamagnetic nanogels that serve as dual diagnostic and delivery platforms, emphasizing their potential for clinical translation despite existing challenges. The incorporation of diagnostic imaging agents into hydrogels enhances tumor visualization and therapeutic monitoring. Lee et al. [12] highlight multifunctional hydrogels embedded with magnetic nanoparticles, fluorescent dyes, and radiolabeled isotopes, which collectively improve real-time imaging and treatment efficacy. These systems exemplify the convergence of diagnostic and therapeutic modalities within a biocompatible matrix.

Addressing the challenge of delivering multiple therapeutics with synchronized release, Liu et al. [13] focus on hybrid nanocarriers powered by functional nucleic acids. These platforms enable the codelivery of hydrophilic and hydrophobic drugs with tumor-specific targeting, which is crucial for overcoming multidrug resistance and achieving precise combination therapy. Furthermore, the design of stimuli-responsive hybrid hydrogels offers tunable control over drug release and mechanical properties. Chang et al. [14] discussed how integrating nanomaterials with polymer networks can produce multifunctional platforms capable of real-time monitoring and combined chemo-immunotherapy, thus advancing the scope of personalized treatment strategies.

In summary, recent literature underscores the importance of multifunctional nanosystems that combine real-time monitoring with controlled, tumor-specific drug release. These platforms leverage diverse nanomaterials—ranging from hybrid nanoparticles and nanogels to hydrogels and magnetoliposomes—to enhance diagnostic accuracy, therapeutic precision, and clinical translatability in oncology. Continued innovation in this field aims to overcome current limitations and realize the full potential of nanotechnology in precision cancer therapy. The field of oncology is witnessing a transformative shift towards precision medicine, where treatment strategies are tailored to the individual characteristics of each patient’s tumor. Multifunctional nanosystems have emerged as pivotal tools in this paradigm, offering capabilities for real-time monitoring and controlled release of therapeutic agents specifically targeting tumor cells. These nanosystems integrate diagnostic and therapeutic functionalities, enabling a more effective and personalized approach to cancer treatment.